Prosthetic Heart Valves: Catering for the Few
Overview
Affiliations
Prosthetic heart valves epitomize both the triumphant advance of cardiac surgery in its early days and its stagnation into a retrospective, exclusive first world discipline of late. Fifty-two years after the first diseased heart valve was replaced in a patient, prostheses largely represent the concepts of the 1960s with many of their design-inherent complications. While the sophisticated medical systems of the developed world may be able to cope with sub-optimal replacements, these valves are poorly suited to the developing world (where the overwhelming majority of potential valve recipients reside), due to differences in age profiles and socio-economic circumstances. Therefore, it is the latter group which suffered most from the sluggish pace of developments. While it previously took less than 7 years for mechanical heart valves to develop from the first commercially available ball-in-cage valve to the tilting pyrolytic-carbon disc valve, and another 10 years to arrive at the all-carbon bi-leaflet design, only small incremental improvements have been achieved since 1977. Similarly, bioprosthetic valves saw their last major break-through development in the late 1960s when formalin fixation was replaced by glutaraldehyde cross linking. Since then, poorly understood so-called 'anti-calcification' treatments were added and the homograft concept rediscovered under the catch-phrase 'stentless'. Still, tissue valves continue to degenerate fast in younger patients, making them unsuitable for developing countries. Yet, catheter-delivered prostheses almost exclusively use bioprosthetic tissue, thereby reducing one of the most promising developments for patients of the developing world into a fringe product for the few first world recipients. With tissue-engineered valves aiming at the narrow niche of congenital malformations and synthetic flexible leaflet valves being in their fifth decade of low-key development, heart valve prostheses seem to be destined to remain an unsatisfying and exclusive first world solution for a long time to come.
Rethinking mechanical heart valves in the aortic position: new paradigms in design and testing.
Chakraborty S, Simon M, Bellofiore A Front Cardiovasc Med. 2025; 11:1458809.
PMID: 39949724 PMC: 11822478. DOI: 10.3389/fcvm.2024.1458809.
Calcific aortic stenosis: omics-based target discovery and therapy development.
Blaser M, Back M, Luscher T, Aikawa E Eur Heart J. 2024; 46(7):620-634.
PMID: 39656785 PMC: 11825147. DOI: 10.1093/eurheartj/ehae829.
A value hierarchy for inclusive design of heart valve implants in regenerative medicine.
De Kanter A, van Daal M, Gunn C, Bredenoord A, de Graeff N, Jongsma K Regen Med. 2024; 19(6):289-301.
PMID: 39177570 PMC: 11346526. DOI: 10.1080/17460751.2024.2357500.
Zilla P, Human P, Pennel T Front Cardiovasc Med. 2024; 11:1347838.
PMID: 38404722 PMC: 10884232. DOI: 10.3389/fcvm.2024.1347838.
Development and testing of a transcatheter heart valve with reduced calcification potential.
Weich H, Botes L, Doubell A, Jordaan J, Lewies A, Marimuthu P Front Cardiovasc Med. 2023; 10:1270496.
PMID: 38124891 PMC: 10731034. DOI: 10.3389/fcvm.2023.1270496.